Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Analysts Are Bullish on These Healthcare Stocks: Eagle Pharmaceuticals (EGRX), Actinium Pharmaceuticals (ATNM)
02:27pm, Friday, 17'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Actinium Pharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: Eagle Pharmaceuticals (EGRX), Actinium Pharmaceuticals (ATNM)
02:27pm, Friday, 17'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals
Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by BidaskClub
09:48am, Thursday, 16'th Apr 2020
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesda
Amphastar Pharmaceuticals (AMPH) Receives a Hold from Needham
09:48am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) today. The company's shares closed last Wednesday at $16.19.
Amphastar Pharmaceuticals (AMPH) Receives a Hold from Needham
09:48am, Thursday, 16'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Hold
rating on Amphastar Pharmaceuticals (
AMPH
–
Research Report
) today. The company’s shares closed last Wednesday at $16.19.
According to
TipRanks.c
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
09:27am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
09:27am, Thursday, 16'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Wednesday at
G.Research Comments on Collegium Pharmaceutical Inc's FY2023 Earnings (NASDAQ:COLL)
07:00am, Thursday, 16'th Apr 2020
Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities research analysts at G.Research cut their FY2023 earnings per share estimates for Collegium Pharmaceutical in a report released on Monday, April
FY2020 EPS Estimates for Collegium Pharmaceutical Inc Decreased by Analyst (NASDAQ:COLL)
06:24am, Thursday, 16'th Apr 2020
Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities research analysts at G.Research lowered their FY2020 earnings per share estimates for Collegium Pharmaceutical in a report released on Monday, A
Head-To-Head Contrast: Axovant Sciences (NASDAQ:AXON) and Collegium Pharmaceutical (NASDAQ:COLL)
05:22am, Thursday, 16'th Apr 2020
Axovant Sciences (NASDAQ:AXON) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strengt
Piper Sandler Remains a Hold on Teva Pharmaceutical Industries (TEVA)
03:43pm, Wednesday, 15'th Apr 2020
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Teva Pharmaceutical Industries (TEVA), with a price target of
Piper Sandler Remains a Hold on Teva Pharmaceutical Industries (TEVA)
03:43pm, Wednesday, 15'th Apr 2020
In a report released today,
David Amsellem
from Piper Sandler maintained a
Hold
rating on Teva Pharmaceutical Industries (
TEVA
–
Research Report
), with a price target of
$8.00
. The company’s sh
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals (MDGL) and CareDx (CDNA)
11:22am, Wednesday, 15'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
H.C. Wainwright Keeps a Buy Rating on Entasis Therapeutics Holdings (ETTX)
11:18am, Tuesday, 14'th Apr 2020
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings (ETTX) today and set a price target of $5.00. The company's
